Amal Nafea J. Alharbi

Epidemiology and Management of Acquired Angioedema Due to C1 Inhibitor Deficiency

Mohammed Olaythah Alraddadi, Yousef Hussain J. Alharthi, Rayyan Fahad H. Altemani, Wejdan Mohammed S. Alshehri, Amal Nafea J. Alharbi, Raghad Saud A. Albalawi, Khawla Abdulrahman S. Alzahrani, Shuruq Mousa D. Albalawi, Sultan Suliman Q. Al-Ruwaili, Sultan Faraj Alruwaili, Mousa Amer M. Alshehri, Asma Saleh S. Alruwaili, Sarah Mohammad M. Ali, Ahmad Arafat A. Abualaz & Marah Saud Alenezi · Journal of Pharmaceutical Research International · 2021

AAE-C1-INH (acquired angioedema owing to C1-inhibitor (C1-INH) deficiency) is a dangerous illness that can lead to asphyxiation due to laryngeal edoema. Only around 1% to 2% of angioedema cases are classified as HAE or AAE, with HAE being 10 times more prevalent than AAE. The sol...

Open access Research Article 10.9734/jpri/2021/v33i57B34034

Role of Anti-VEGF (Bevacizumab) in Management of Neovascular Glaucoma: A Review

Abdulrahman Arshed N. Alharfy, Marwan Saleh D. Albalawi, Abdulmajeed Mousa Alzahrani, Ruby Naif M. Alsubaie, Amani Ahmad S. Albalawi, Waad Ali Alkaabneh, Abdullah Ibrahim Altidlawi, Amal Nafea J. Alharbi, Afnan Mohammed H. Almutairi & Rola Ali S. Alotabi · Journal of Pharmaceutical Research International · 2021

Neovascular glaucoma (NVG) is an aggressive type of glaucoma, which often results in poor visual outcomes. Antivascular endothelial growth factor is frequently used for various conditions in which VEGF release is induced in response to retinal ischemia. Bevacizumab is a humanized...

Open access Research Article 10.9734/jpri/2021/v33i40A32237